主要已開發國家到2021年的多發性骨髓瘤 (MM) 治療藥市場:盛行率的增加、Revlimid的持續成功、新興補助治療促進成長
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
|出版日期||內容資訊||英文 119 Pages
|主要已開發國家到2021年的多發性骨髓瘤 (MM) 治療藥市場:盛行率的增加、Revlimid的持續成功、新興補助治療促進成長 Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments|
|出版日期: 2015年07月01日||內容資訊: 英文 119 Pages||
多發性骨髓瘤(MM)，是特徵為骨髓中的漿細胞增生的血液學性惡性腫瘤。在多發性骨髓瘤 (MM) 開發平台上，分子類型和治療標的範圍遼闊包含267種產品。
本報告提供主要已開發國家的多發性骨髓瘤 (MM) 治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10-15 years, and have improved median survival rates by about 50%.
The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.